Lifesci Capital Upgrades Liquidia (NASDAQ:LQDA) to “Strong-Buy”

Liquidia (NASDAQ:LQDA) was upgraded by equities research analysts at Lifesci Capital to a “strong-buy” rating in a research note issued to investors on Wednesday, Zacks.com reports.

A number of other analysts also recently issued reports on LQDA. Oppenheimer started coverage on Liquidia in a research note on Tuesday, June 25th. They issued a “market perform” rating on the stock. HC Wainwright cut their target price on Liquidia from $32.00 to $29.00 and set a “buy” rating on the stock in a research report on Tuesday, August 20th. Needham & Company LLC reissued a “buy” rating and set a $25.00 target price on shares of Liquidia in a research report on Monday, August 19th. Bank of America cut their target price on Liquidia from $24.00 to $23.00 and set a “buy” rating on the stock in a research report on Tuesday, August 20th. Finally, BTIG Research cut their target price on Liquidia from $29.00 to $25.00 and set a “buy” rating on the stock in a research report on Monday, August 19th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Liquidia has a consensus rating of “Moderate Buy” and an average target price of $24.00.

Liquidia Trading Up 0.8 %

NASDAQ LQDA opened at $10.09 on Wednesday. The stock’s 50 day moving average is $10.47 and its 200 day moving average is $12.28. Liquidia has a 12 month low of $5.71 and a 12 month high of $16.99. The stock has a market cap of $771.02 million, a PE ratio of -6.47 and a beta of 0.22.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). Liquidia had a negative return on equity of 183.57% and a negative net margin of 755.46%. The business had revenue of $3.66 million during the quarter, compared to analysts’ expectations of $7.92 million. On average, analysts forecast that Liquidia will post -1.71 EPS for the current fiscal year.

Insider Buying and Selling at Liquidia

In other Liquidia news, CEO Roger Jeffs sold 8,053 shares of the company’s stock in a transaction on Friday, July 12th. The stock was sold at an average price of $12.53, for a total value of $100,904.09. Following the transaction, the chief executive officer now owns 818,932 shares of the company’s stock, valued at approximately $10,261,217.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CEO Roger Jeffs sold 8,053 shares of the stock in a transaction on Friday, July 12th. The stock was sold at an average price of $12.53, for a total transaction of $100,904.09. Following the transaction, the chief executive officer now owns 818,932 shares of the company’s stock, valued at approximately $10,261,217.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Caligan Partners Lp purchased 150,000 shares of the company’s stock in a transaction dated Friday, August 30th. The shares were purchased at an average cost of $9.51 per share, for a total transaction of $1,426,500.00. Following the transaction, the director now directly owns 6,994,997 shares in the company, valued at approximately $66,522,421.47. The disclosure for this purchase can be found here. Insiders have sold 21,422 shares of company stock valued at $256,998 in the last quarter. 31.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of LQDA. Patient Square Capital LP acquired a new stake in Liquidia in the first quarter valued at approximately $105,942,000. Farallon Capital Management LLC purchased a new stake in Liquidia in the first quarter valued at $30,311,000. Vestal Point Capital LP purchased a new stake in shares of Liquidia in the 4th quarter valued at $12,331,000. Kynam Capital Management LP raised its holdings in shares of Liquidia by 34.9% in the 4th quarter. Kynam Capital Management LP now owns 2,698,324 shares of the company’s stock valued at $32,461,000 after buying an additional 698,324 shares during the period. Finally, BNP Paribas Financial Markets raised its holdings in shares of Liquidia by 119.4% in the 1st quarter. BNP Paribas Financial Markets now owns 230,248 shares of the company’s stock valued at $3,396,000 after buying an additional 125,315 shares during the period. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).